Listing of Color Additives Exempt From Certification; Food, Drug, and Cosmetic Labeling: Cochineal Extract and Carmine Declaration
FDA proposes requiring explicit declaration of cochineal extract and carmine on cosmetic labels, replacing generic 'color added' listings.
Aforeworn detected this change in the Cosmetics & Personal-Care (MoCRA) space on July 6, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Medium urgency. All cosmetic manufacturers, importers, and distributors using cochineal extract or carmine as color additives. should confirm how it applies to their specific situation before acting. There is a time constraint attached: Comment period ends 60 days after publication (March 31, 2006). Final rule compliance date to be determined.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Cosmetics & Personal-Care (MoCRA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
Proposed rule mandates specific ingredient declaration (e.g., 'Cochineal Extract' or 'Carmine') on labels, rather than generic 'color added'.
Who it affects
All cosmetic manufacturers, importers, and distributors using cochineal extract or carmine as color additives.
What you must do
Review product formulations for cochineal extract or carmine; update labels to declare these ingredients explicitly.
Deadline
Comment period ends 60 days after publication (March 31, 2006). Final rule compliance date to be determined.
Never miss a change like this again
Aforeworn watches Cosmetics & Personal-Care (MoCRA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Cosmetics & Personal-Care (MoCRA)
- FDA Launches One-Day Inspectional Assessments to Strengthen and Expand Oversight
- FDA Grants Seventh Approval under the National Priority Voucher Pilot Program
- FDA Issues Guidance to Improve Collection of Pregnancy Safety Data for Drugs and Biologics
- FDA Expands AI Capabilities and Completes Data Platform Consolidation
- FDA Approves First Treatment for Chronic Hepatitis Delta Virus (HDV) Infection